BA
BAX.US Baxter International Inc
- Market cap
- USD 13.4B
- P/E
- -
- P/B
- 2.05x
- ROE
- 8.3%
- Dividend yield
- 2.61%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BAX.US undervalued?
Graham numberThe Graham number of Baxter International Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Baxter International Inc fundamental analysis
No fundamental analysis for Baxter International Inc yet.
Baxter International Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Baxter International Inc
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipm…
Full company profileBaxter International Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Baxter International Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 10.2B | 10.6B | 11.1B | 11.4B | 11.7B | 12.1B | 10.1B | 10.4B | 10.6B | 11.2B | 11.5B |
| Gross Profit | 4.12B | 4.47B | 4.76B | 4.76B | 4.59B | 4.72B | 3.55B | 4.15B | 3.98B | 3.38B | 3.89B |
| Operating Income | 745M | 1.29B | 1.58B | 1.77B | 1.62B | 1.35B | -2.85B | 707M | 14.0M | -308M | 677M |
| EBITDA | 5.84B | 1.94B | 2.48B | 1.87B | 2.27B | 2.19B | -1.76B | 1.73B | 1.12B | 766M | 1.67B |
| Net Income | 4.97B | 602M | 1.55B | 1.00B | 1.10B | 1.28B | -2.43B | 2.66B | -649M | -957M | 540M |
| EPS | 9.01 | 1.08 | 2.83 | 1.93 | 2.13 | 2.53 | -4.83 | 5.25 | -1.27 | -1.87 | 1.04 |
| Balance Sheet | |||||||||||
| Total Assets | 15.5B | 17.1B | 15.7B | 18.2B | 20.0B | 33.5B | 28.3B | 28.3B | 25.8B | 20.1B | 19.4B |
| Total Liabilities | 7.27B | 8.00B | 7.85B | 10.3B | 11.3B | 24.4B | 22.4B | 19.8B | 18.8B | 14.0B | 12.9B |
| Shareholders' Equity | 8.29B | 9.12B | 7.84B | 7.88B | 8.69B | 9.08B | 5.83B | 8.40B | 6.96B | 6.13B | 6.50B |
| Cash & Short-term Investments | 2.80B | 3.39B | 1.84B | 3.34B | 3.73B | 2.95B | 1.72B | 3.08B | 1.76B | 1.97B | 1.98B |
| Total Debt | 2.78B | 3.51B | 3.49B | 5.96B | 6.80B | 18.3B | 17.2B | 14.1B | 13.4B | 10.0B | 8.81B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.65B | 1.71B | 2.02B | 2.10B | 1.87B | 2.22B | 1.21B | 1.73B | 1.02B | 845M | 1.41B |
| Capital Expenditure | 719M | 616M | 659M | 696M | 709M | 743M | 679M | 436M | 460M | 522M | 667M |
| Free Cash Flow | 935M | 1.10B | 1.36B | 1.41B | 1.16B | 1.48B | 532M | 1.29B | 559M | 323M | 741M |
| Ratios | |||||||||||
| ROE | 59.9% | 6.6% | 19.7% | 12.7% | 12.7% | 14.1% | -41.7% | 31.6% | -9.3% | -15.6% | 8.3% |
| ROA | 31.9% | 3.5% | 9.8% | 5.5% | 5.5% | 3.8% | -8.6% | 9.4% | -2.5% | -4.8% | 2.8% |
| Net Profit Margin | 48.9% | 5.7% | 13.9% | 8.8% | 9.4% | 10.6% | -24.2% | 25.6% | -6.1% | -8.5% | 4.7% |
| Debt to Equity | 0.34x | 0.38x | 0.44x | 0.76x | 0.78x | 2.02x | 2.95x | 1.68x | 1.93x | 1.63x | 1.35x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Baxter International Inc dividends
- Dividend yield
- 2.61%
- Forward dividend
- 0.04 USD
- Payout ratio
- -
- Ex-dividend date
- Nov 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 348M | 0.68 | - |
| 2024 | USD 590M | 1.16 | - |
| 2023 | USD 586M | 1.16 | 22.1% |
| 2022 | USD 573M | 1.14 | - |
| 2021 | USD 530M | 1.04 | 41.3% |
| 2020 | USD 473M | 0.91 | 42.9% |
| 2019 | USD 423M | 0.82 | 42.3% |
| 2018 | USD 376M | 0.69 | 24.3% |
| 2017 | USD 315M | 0.57 | 52.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1841:1000 on Jul 1, 2015.
Who owns Baxter International Inc
- Insiders 0.34%
- Institutions 99.66%
- Public & others 0.00%
- Shares outstanding 517M
- Free float 515M
Top funds holding BAX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Dodge & Cox Stock I | 36.1M | 6.97% | -6.59% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 16.4M | 3.18% | +0.10% | Sep 2026 |
| Vanguard 500 Index Investor | 13.6M | 2.62% | -1.05% | Sep 2026 |
| Vanguard Small Cap Index | 11.6M | 2.25% | -2.02% | Sep 2026 |
| Vanguard Windsor Investor Shares | 10.2M | 1.98% | -1.97% | Sep 2026 |
| BlackRock Equity Dividend Instl | 10.2M | 1.98% | -29.44% | Sep 2026 |
| Fidelity Series Large Cap Stock | 9.15M | 1.77% | +1.37% | Sep 2026 |
| Invesco S&P 500® Equal Weight ETF | 8.09M | 1.56% | +0.17% | Oct 2026 |
| Strategic Advisers Fidelity US TtlStk | 7.11M | 1.37% | +0.57% | Sep 2026 |
| iShares Core S&P 500 ETF | 6.89M | 1.33% | +0.17% | Oct 2026 |
| Vanguard MStar Small Cap Value Index | 6.85M | 1.33% | +0.44% | Sep 2026 |
| Fidelity 500 Index | 6.72M | 1.30% | +0.22% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 6.34M | 1.23% | -0.25% | Oct 2026 |
| Fidelity Growth & Income | 4.77M | 0.92% | 0.00% | Sep 2026 |
| FPA Crescent | 4.54M | 0.88% | 0.00% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 3.78M | 0.73% | +0.88% | Oct 2026 |
| Vanguard Selected Value Inv | 3.67M | 0.71% | 0.00% | Sep 2026 |
| Dodge & Cox Global Stock I | 3.39M | 0.66% | 0.00% | Sep 2026 |
| Fidelity Large Cap Stock | 3.32M | 0.64% | 0.00% | Sep 2026 |
| Vanguard Global Equity Inv | 2.93M | 0.57% | 0.00% | Sep 2026 |
Top institutions holding BAX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 81.8M | 15.82% | +3.07% | Jun 2026 |
| Pzena Investment Management, LLC | 65.3M | 12.62% | +1.19% | Jun 2026 |
| Dodge & Cox | 58.4M | 11.29% | +1.98% | Jun 2026 |
| FMR Inc | 53.9M | 10.42% | +16.53% | Jun 2026 |
| Vanguard Capital Management, LLC | 33.8M | 6.52% | +0.74% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 24.1M | 4.65% | +0.27% | Jun 2026 |
| State Street Corp | 20.6M | 3.98% | +3.11% | Jun 2026 |
| Greenhaven Associates Inc | 14.3M | 2.76% | -0.16% | Jun 2026 |
| Geode Capital Management, LLC | 14.1M | 2.73% | +2.62% | Jun 2026 |
| Amvescap Plc. | 12.4M | 2.39% | -5.79% | Jun 2026 |
| UBS Group AG | 9.53M | 1.84% | +120.61% | Jun 2026 |
| First Pacific Advisors, LP | 7.62M | 1.47% | +13.69% | Jun 2026 |
| The Goldman Sachs Group Inc | 7.15M | 1.38% | +84.79% | Jun 2026 |
| Equity Investment Corp | 6.89M | 1.33% | +8.10% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 6.36M | 1.23% | -13.45% | Jun 2026 |
| Bank of America Corp | 6.24M | 1.21% | +1.16% | Jun 2026 |
| State Farm Mutual Automobile Ins Co | 6.23M | 1.20% | 0.00% | Jun 2026 |
| Charles Schwab Investment Management Inc | 6.00M | 1.16% | +7.28% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 4.93M | 0.95% | -12.08% | Sep 2026 |
| Northern Trust Corp | 4.86M | 0.94% | +11.89% | Jun 2026 |
Baxter International Inc company profile
- Company name
- Baxter International Inc
- Ticker
- BAX.US
- Exchange
- USA Stocks
- Listed since
- Oct 27, 1981
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 37,500
- Fiscal year end
- December
- Address
- One Baxter Parkway, Deerfield, IL, United States, 60015
- Phone
- 224 948 2000
- Website
- baxter.com
About Baxter International Inc
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Baxter International Inc management
10- Mr. Andrew P. HiderCEO, Pres., Interim Group Pres. of Medical Products & Therapies and Director · born 1977
- Mr. David S. RosenbloomExecutive VP & General Counsel · born 1960
- Ms. Maria SorianoGroup President of Infusion Therapies & Platforms
- Mr. John Terence RogersExecutive VP & CFO · born 1969
- Mr. Bernie HeineInterim Chief Accounting Officer & Controller · born 1986
- Mr. Charles PatelSenior VP & Chief Information Officer · born 1970
- Mr. Kevin MoranVice President & Head of Investor Relations
- Ms. Stacey EisenSVP, Chief Communications Officer & Corporate Marketing and President of Baxter Foundation
- Ms. Cynthia CarlisleExecutive VP & Chief Human Resources Officer · born 1975
- Mr. James W. BorziExecutive VP & Chief Supply Chain Officer · born 1963